Pfizer Q3 2026 earnings
Revenue and EPS declined sequentially, with adjusted EBITDA margin expanding year-over-year despite lower sales.
Headline numbers
| Metric | Actual | YoY | QoQ | 8-K location |
|---|---|---|---|---|
| Revenue | $13.5B | -3% | -4% | Ex. 99.1, income statement |
| EPS (GAAP) | $0.22 | -19% | -0.10 | Ex. 99.1, income statement |
| EPS (adjusted) | $0.78 | +5% | -0.02 | Ex. 99.1, income statement |
| Net income | $2.0B | -19% | -0.8 | Ex. 99.1, income statement |
| Adj. EBITDA | $3.8B | +2% | -0.2 | Ex. 99.1, income statement |
| Adj. EBITDA margin | 28.2% | +1.2 pp | -0.3 pp | Ex. 99.1, income statement |
Revenue breakdown
| Segment | Actual | YoY | Share of revenue | Note |
|---|---|---|---|---|
| Innovation | $6.1B | -4% | 45% | Lower sales of Comirnaty and Xeljanz |
| Established Products | $7.4B | -2% | 55% | Lower sales of Lyrica and Sutent |
Margins and costs
- Gross margin 79.2% (prior 79.5%, change -0.3 pp)
- Operating expenses $9.7B (+3% YoY)
- One-offs in the quarter Credit losses on loans: $0.2B; Other income (expense): $0.1B
- Effective tax rate 20.0% (prior-year 20.0%, year-to-date 20.0%)
- Non-GAAP bridge Adds back credit losses on loans and other income (expense) to arrive at adjusted results; these add-backs recur.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Free cash flow | $2.5B | $2.8B | $2.6B | -0.3 |
| R&D expenses | $2.6B | $2.6B | $2.7B | -0.1 |
| SG&A expenses | $7.1B | $7.0B | $7.0B | +0.1 |
Guidance
| Metric | Guide | Prior guide | Change |
|---|---|---|---|
| Revenue | $13.8B - $14.2B | $13.8B - $14.2B | No change |
| EPS (adjusted) | $0.78 - $0.82 | $0.78 - $0.82 | No change |
| Adj. EBITDA margin | 28.0% - 28.5% | 28.0% - 28.5% | No change |
What drove it
- Revenue story Innovation and Established Products both declined sequentially by 4% and 2%, respectively, driven by lower sales of Comirnaty, Xeljanz, Lyrica, and Sutent.
- EPS story Adjusted EPS grew 5% year-over-year, supported by higher adjusted EBITDA, but declined sequentially due to lower revenue and a slight margin compression.
- One-off check Credit losses on loans of $0.2B and other income (expense) of $0.1B are non-recurring items impacting GAAP results.
The good
- Adjusted EBITDA margin expanded 1.2 pp year-over-year to 28.2%
- Adjusted EPS grew 5% year-over-year
The bad
- Revenue declined 4% sequentially and 3% year-over-year
- Free cash flow declined 0.3 sequentially
The ugly
- none
Open questions
- The release does not quantify the impact of the lower sales of Comirnaty, Xeljanz, Lyrica, and Sutent on the sequential decline.
- The release does not provide a breakdown of the $0.1B other income (expense) item.
Full release
Pfizer (PFE) earnings release, November 3, 2026
Attachments
Seq Document Description
───────────────────────────────────────────────────────────────────────────────
2 pfe-9272026xex99.htm Additional exhibits